Hormone Receptor Positive Breast Cancer

P3, N=192, Recruiting, Sun Yat-sen University | Enrolling by invitation --> Recruiting

P=N/A, N=85, Recruiting, Mayo Clinic | Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: May 2026 --> Sep 2026

Real-world data reveal drug- and age-specific toxicity differences. Ribociclib and abemaciclib pose higher risks in older adults compared to palbociclib, supporting the need for personalized treatment and careful monitoring in older patients.

This study suggests that selected patients with de novo mBC and locoregional oligoprogression can benefit from breast surgery while maintaining the same systemic treatment, particularly in the setting of HER2-positive disease or a pre-oligoprogression PFS >1 year.

P1, N=18, Recruiting, Shanghai Juncell Therapeutics | Trial primary completion date: Nov 2025 --> Nov 2026

Ribociclib (Ribo) and Abemaciclib (Abe) are new-generation CDK inhibitors approved for use in breast cancer treatment. Some molecular mechanisms were elucidated by revealing the synergistic effect of FA combined with Ribo and/or Abe in both HR positive and HR negative breast cancer and its possible toxicity or protection on normal breast cells. The present findings suggest that FA is a viable candidate for adjuvant or neoadjuvant treatment in combination with Ribo and/or Abe, as an alternative to Letrozole or Fulvestrant, which have been associated with significant adverse effects in clinical settings.

Yellow laser exposure triggers targeted cell death and cytotoxic effects in breast cancer cells, especially in ER-positive MCF-7 cells. The findings suggest that yellow laser PBMT is promising as a treatment approach for certain breast cancers.

Interventions to prevent or treat CRCI are needed to improve the long-term quality of life of these patients treated with chemotherapy. ClinicalTrials.gov Identifier: NCT01272037.

The biological basis arises from the dual function of monocytes in promoting tumor-supportive environments and lymphocytes in facilitating immune monitoring. Through the capture of this immunological interaction, MLR acts as a low-risk and affordable method for risk assessment and treatment choices adapted to molecular subtype traits.

This case highlights that isolated adrenal metastasis can occur even after prolonged remission, with hypercalcemia as the sole presenting feature. It emphasizes the need for long-term surveillance in breast cancer survivors and the potential role of surgery in managing isolated adrenal metastases.

We summarize intensive treatment methods for T1N0M0 HR+/HER2- breast cancer patients, which extend beyond the standard 5-year tamoxifen (TAM)-based adjuvant ET. These methods include intensive ET, poly(ADP-ribose) polymerase (PARP) inhibitors, other targeted therapies, antibody-drug conjugates, oral chemotherapy, immunotherapy, and enhanced prevention of bone metastasis. This review provides a foundation for developing personalized adjuvant treatment strategies for patients with T1N0M0 HR+/HER2- breast cancer.

The discovered LPP phenotype defines a small, high-risk subset warranting external validation. Given the retrospective, single-system design of the study, it is imperative to interpret the discovered phenotype features as hypothesis-generating, rather than as definitive evidence.